在接受不同抗癌治疗的实体瘤患者中，接种SARS-CoV-2 mRNA加强针的体液效应。
Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments.
作者信息
Piubelli Chiara, Valerio Matteo, Verzè Matteo, Nicolis Fabrizio, Mantoan Carlotta, Zamboni Sonia, Perandin Francesca, Rizzi Eleonora, Tais Stefano, Degani Monica, Caldrer Sara, Gobbi Federico Giovanni, Bisoffi Zeno, Gori Stefania
机构信息
Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.
Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.
出版信息
Front Oncol. 2023 Feb 22;13:1089944. doi: 10.3389/fonc.2023.1089944. eCollection 2023.
INTRODUCTION
Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatment. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose.
METHODS
In our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies.
RESULTS AND DISCUSSION
Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.
引言
癌症患者感染新型冠状病毒严重急性呼吸综合征（SARS-CoV-2）时面临严重并发症风险。强烈建议这些患者接种SARS-CoV-2疫苗，优先使用信使核糖核酸（mRNA）疫苗。癌症患者的抗体反应各不相同，取决于癌症类型和抗肿瘤治疗。实体瘤患者在接种第二剂疫苗后，已证实其抗体反应与健康受试者相似。仅有少数研究探讨了两剂疫苗接种后的免疫持续时间以及第三剂疫苗的效果。
方法
在我们的研究中，我们对273名处于不同阶段并接受不同抗癌治疗的实体瘤患者进行了研究。
结果与讨论
我们的分析表明，疫苗加强剂量后的中和抗体持久性和体液反应不依赖于肿瘤类型、抗癌治疗的阶段或类型。
Zotero 插件